grant
Oral digoxin for the treatment of NASH
NIHUS FederalResearch GrantFY2026(TNF)-αAffectAfter CareAfter-TreatmentAftercareAlcohol associated hepatitisAlcohol hepatitisAlcohol induced hepatitisAlcohol related hepatitisAlcoholic HepatitisAnti-InflammatoriesAnti-Inflammatory AgentsAnti-inflammatoryAntigen-Antibody ComplexAreaB cell differentiation factorB cell stimulating factor 2B-Cell Differentiation FactorB-Cell Differentiation Factor-2B-Cell Stimulatory Factor-2BCDFBSF-2BSF2Basal Transcription FactorBasal transcription factor genesBindingBiopsyBlood PlasmaBlood SerumBlood monocyteBody TissuesCCL2CCL2 geneCCL20CCL20 geneCRG-2CSIFCSIF-10CXCL1CXCL1 geneCXCL10CXCL10 geneCachectinCardiacCardiac GlycosidesCardiotonic SteroidsCaringCell BodyCell DifferentiationCell Differentiation processCellsChemokine, CC Motif, Ligand 2Chemokine, CC Motif, Ligand 20CholesterolCirrhosisClinicClinicalClinical TrialsCytokine Synthesis Inhibitory FactorDataDevelopmentDigoxinDoseDouble-Blind MethodDouble-Blind StudyDouble-BlindedDouble-Masked MethodDouble-Masked StudyDrug IndustryDrugsELISAEconomicsEnzyme-Linked Immunosorbent AssayEpidemicEthanol-induced hepatitisExodus 1Fatty LiverFibrosisFlow CytofluorometriesFlow CytofluorometryFlow CytometryFlow MicrofluorimetryFlow MicrofluorometryFosteringGRO1GROAGene TranscriptionGeneral Transcription Factor GeneGeneral Transcription FactorsGeneric DrugsGenesGenetic TranscriptionGoalsGranzymeHPGFHealthHepaticHepatic CancerHepatic CellsHepatic CirrhosisHepatic Parenchymal CellHepatic Stellate CellHepatocyteHepatocyte-Stimulating FactorHumanHybridoma Growth FactorHypoxia Inducible FactorIFI10IFN-beta 2IFNB2IL-10IL-6IL10IL10AIL6 ProteinINP10IP-10ImmuneImmune ComplexImmune responseImmunesImmunobiologyImmunohistochemistryImmunohistochemistry Cell/TissueImmunohistochemistry Staining MethodImmunologic StimulationImmunological StimulationImmunomodulationImmunophysiologyImmunostimulationIn VitroInflammationInflammatoryInterdisciplinary ResearchInterdisciplinary StudyInterleukin 10 PrecursorInterleukin-10Interleukin-6InvestigationIto CellK ATPaseLARCLanoxinLipopolysaccharidesLiverLiver CellsLiver CirrhosisLiver FibrosisLiver SteatosisLiver lesion biopsyMCAFMCP-1MCP1MGI-2MGSAMIP3AMOB-1MacrophageMacrophage Inflammatory Protein 3-AlphaMacrophage-Derived TNFMalignant neoplasm of liverMarrow monocyteMediatingMedical InspectionMedicationMiceMice MammalsMissionModern ManMolecular InteractionMonocyte Chemoattractant Protein-1Monocyte Chemotactic Protein-1Monocyte Chemotactic and Activating FactorMonocyte Chemotactic and Activating ProteinMonocyte Chemotactive and Activating FactorMonocyte Secretory Protein JEMonocyte-Derived TNFMortality DeterminantsMultidisciplinary CollaborationMultidisciplinary ResearchMurineMusMyelogenousMyeloidMyeloid CellsMyeloid Differentiation-Inducing ProteinMφNAFLDNASHNational Institutes of HealthNon-proprietary DrugsNonproprietary DrugsNuclearOralPDGFPatientsPeripheral Blood LymphocytePharmaceutic IndustryPharmaceutical IndustryPharmaceutical PreparationsPhysical ExaminationPlacebo ControlPlacebosPlasmaPlasma SerumPlasmacytoma Growth FactorPlatelet-Derived Growth FactorPopulationProductionPublic HealthPublishingPyruvate KinaseQOLQuality of lifeRNA ExpressionRNA SeqRNA sequencingRNAseqRandomizedReportingResearchReticuloendothelial System, Serum, PlasmaRoleSCYA2SCYA20SCYB1SCYB10SafetySerumSham TreatmentSmall Inducible Cytokine A2Small Inducible Cytokine Subfamily A, Member 20Staining methodStainsSteatohepatitisSurvey InstrumentSurveysT-CellsT-LymphocyteTNFTNF ATNF AlphaTNF geneTNF-αTNFATNFαTarget PopulationsTestingTherapeuticTimeTissuesTitrationsTranscriptionTranscription ActivationTranscription Factor Proto-OncogeneTranscription factor genesTranscriptional ActivationTranslationsTumor Necrosis FactorTumor Necrosis Factor-alphaUnited StatesUnited States National Institutes of HealthWorkacute liver injurycardiac functioncellular differentiationchronic hepatic diseasechronic hepatic disorderchronic liver diseasechronic liver disorderchronic liver injurycirrhoticclinical practiceclinical relevanceclinically relevantcytokinedevelopmentaldrug/agenteconomiceffective therapyeffective treatmentend stage liver diseaseend stage liver failureenzyme linked immunoassayfibrotic liverflow cytophotometryfunction of the heartgIP-10healthy volunteerheart functionhepatic body systemhepatic fibrosishepatic inflammationhepatic organ systemhepatic steatosishepatoprotectionhepatoprotectivehepatosteatosishost responsehuman modelhuman subjectimmune modulationimmune regulationimmune system responseimmunologic reactivity controlimmunomodulatoryimmunoregulationimmunoregulatoryimmunoresponseimprovedin vitro Assayinflamed liverinnovateinnovationinnovativeinterferon beta 2liver biopsyliver cancerliver inflammationliver malignancymalignant liver tumormodel of humanmonocytemouse modelmurine modelnew drug treatmentsnew drugsnew pharmacological therapeuticnew therapeuticsnew therapynext generation therapeuticsnon-alcohol fatty liver diseasenon-alcohol induced steatohepatitisnon-alcoholic fatty liver diseasenon-alcoholic liver diseasenon-alcoholic steato-hepatitisnon-alcoholic steatohepatitisnonalcoholic fatty liver diseasenonalcoholic steato-hepatitisnonalcoholic steatohepatitisnovel drug treatmentsnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel therapeuticsnovel therapypatient populationperipheral bloodphosphoenol transphosphorylasephosphoenolpyruvate kinasephysical examinationsplacebo controlledpost treatmentpotassium ATPasepreventpreventingprimary end pointprimary endpointrandomisationrandomizationrandomly assignedrepurposingresponsesafety assessmentsham therapyside effectsocial rolethymus derived lymphocytetranscription factortranscriptome sequencingtranscriptomic sequencingtranslation
Description preview
Project Summary/ Abstract
Nonalcoholic steatohepatitis (NASH) has reached epidemic proportions and will result in an immense
burden of chronic liver disease and cirrhosis. Therapeutics for NASH is a very active area of investigation, but
even with development of propriety drugs there will be major issues of financial availability for such a large…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click